Regulation Text
Authority
21 U.S.C. 321,351,352,355,360b,360ddd,360ddd-1,371,374;42 U.S.C. 216,262,263a,264.
Related Warning Letters (2)
- 2025-06-03
CGMP/Finished Pharmaceuticals/Adulterated
Huangshi Hygienic Material Medicine Co., Ltd.
- 2023-01-31
CGMP/Drug Products/Adulterated
Urban Electric Power
Related Guidelines (8)
Current Good Manufacturing Practice Requirements for Combination Products: Guidance for Industry and FDA Staff (Status: Final)
→Preparation of Investigational New Drug Products (Human and Animal): Guidance for Industry (Status: Final)
→Questions and Answers on Current Good Manufacturing Practices for Drugs (Status: Final)
→BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry (Status: Final)
→ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers (Status: Final)
→Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry (Status: Draft)
→Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry: Guidance for Industry (Status: Final)
→Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry (Status: Draft)
→